Impact of Prophylactic Immediate Posttransplant Ganciclovir on Development of Transplant Atherosclerosis

Abstract

TxCAD incidence appears to be lower in patients treated with ganciclovir who are not treated with calcium blockers. Given the limitations imposed by post hoc analysis, a randomized clinical trial is required to address this issue.